Expression of Glypican-3 in Mouse Embryo Stem Cells and its Derived Hepatic Lineage Cells Treated with Diethylnitrosamine in vitro

  • Kim, Young Hee (Department of Biomedical Laboratory Science, Namseoul University) ;
  • Kang, Jin Seok (Department of Biomedical Laboratory Science, Namseoul University)
  • Published : 2013.11.30


To clarify the role of stem cells in hepatocarcinogenesis, glypican-3 (GPC-3) and E-cadherin expression was investigated in embryonic cell lineages. Mouse embryonic stem cells (ESCs), hepatic progenitor cells (HPCs) and hepatocyte like cells (HCs), representing 0, 22 and 40 days of differentiation, respectively, were treated in vitro with diethylnitrosamine (DEN) at four doses (0, 1, 5 and 15 mM; G1, G2, G3 and G4, respectively) for 24 h and GPC-3 and E-cadherin expression was examined by relative quantitative real-time PCR and immunocytochemistry. GPC-3 mRNA expression was significantly different for G4 at day 0 (p<0.001) and for G4 at day 22 (p<0.01) compared with the control (G1). E-cadherin mRNA expression was significantly different for G3 and G4 at day 0 (p<0.05 and p<0.001, respectively), for G2 and G4 (p<0.05 and p<0.001, respectively) at day 22 and for G2 and G4 (p<0.01 and p<0.001, respectively) at day 40 compared with G1. Immunofluorescence staining for GPC-3 showed a membranous and/or granular expression in cytoplasm of ESCs and HPCs and granular and/or diffuse expression in cytoplasm of HCs, which were also stained by E-cadherin. DEN treatment increased GPC-3 expression in ESCs, HPCs and HCs, with increase of E-cadherin expression. Taken together, the expression of GPC-3 was altered by DEN treatment. However, its expression pattern was different at the stage of embryo stem cells and its derived hepatic lineage cells. This suggests that GPC-3 expression may be modulated in the progeny of stem cells during their differentiation toward hepatocytes, associated with E-cadherin expression.


Mouse embryonic stem cell;hepatic lineage cells;hepatocarcinogenesis;glypican-3;diethylnitrosamine


  1. Brambilla G, Martelli A (1993). Human hepatocyte primary cultures in toxicity assessment. Cytotechnol, 11, 6-8.
  2. Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterol, 125, 89.
  3. Fausto N, Campbell JS (2010). Mouse models of hepatocellular carcinoma. In Seminars in liver disease, 30, 87-98.
  4. Filmus J, Church J, Buick R (1988). Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol, 8, 4243-9.
  5. Gomez-Lechon MJ, Castell JV, Donato MT (2010). The use of hepatocytes to investigate drug toxicity. In Hepatocytes, 640, 389-415.
  6. Greenhough S, Medine CN, Hay DC (2010). Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicol, 278, 250-5.
  7. Grozdanov PN, Yovchev MI, Dabeva MD (2006). The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest, 86, 1272-84.
  8. Guillouzo A, Morel F, Fardel O, Meunier B (1993). Use of human hepatocyte cultures for drug metabolism studies. Toxicology, 82, 209-19.
  9. Hamazaki T, Iiboshi Y, Oka M, et al (2001). Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS letters, 497, 15-9.
  10. Hammond AH, Garle MJ, Fry JR (1995). Mechanism of toxicity of precocene II in rat hepatocyte cultures. J Biochem Toxicol, 10, 265-73.
  11. Ho DW, Yang ZF, Yi K, et al (2012). Gene expression profiling of liver cancer stem cells by RNA-sequencing. PloS one, 7, 37159.
  12. Kafert-Kasting S, Alexandrova K, Barthold M, et al (2006). Enzyme induction in cryopreserved human hepatocyte cultures. Toxicol, 220, 117-25.
  13. Kandil DH, Cooper K (2009). Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 16, 125-9.
  14. Kang S-J, Jeong S-H, Kim E-J, et al (2013). Evaluation of hepatotoxicity of chemicals using hepatic progenitor and hepatocyte-like cells derived from mouse embryonic stem cells. Cell biol and toxicol, 29, 1-11.
  15. Maier P (1989). Development of hepatocyte cultures in toxicity testing. Altex, 6, 38.
  16. Nakatsura T, Yoshitake Y, Senju S, et al (2003). Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Bioph Res Commun, 306, 16-25.
  17. Nussler A, Wang A, Neuhaus P, et al (2001). The suitability of hepatocyte culture models to study various aspects of drug metabolism. Altex, 18, 91.
  18. Okura H, Komoda H, Saga A, et al (2009). Properties of hepatocyte-like cell clusters from human adipose tissue-derived mesenchymal stem cells. Tissue Eng Part C Methods, 16, 761-70.
  19. Rambhatla L, Chiu C-P, Kundu P, et al (2003). Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant, 12, 1-11.
  20. Ratanasavanh D, Baffet G, Latinier M, et al (1988). Use of hepatocyte co-cultures in the assessment of drug toxicity from chronic exposure. Xenobiotica, 18, 765-71.
  21. Reich-Slotky R, Bonneh-Barkay D, Shaoul E, et al (1994). Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. J Biol Chem, 269, 32279-85.
  22. Sell S, Dunsford HA (1989). Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. The Am J Pathol, 134, 1347-63.
  23. Shirakawa H, Kuronuma T, Nishimura Y, et al (2009a). Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol, 34, 649-56.
  24. Shirakawa H, Suzuki H, Shimomura M, et al (2009b). Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 100, 1403-7.
  25. Song HH, Shi W, Filmus J (1997). OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem, 272, 7574-7.
  26. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A (2010). Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroentero, 16, 418.
  27. Sung YK, Hwang SY, Park MK, et al (2003). Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Science, 94, 259-62.
  28. Touboul T, Hannan NR, Corbineau S, et al (2010). Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology, 51, 1754-65.
  29. Vesselinovitch S, Koka M, Mihailovich N, Rao K (1984). Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice. J Cancer Res Clin Oncol, 108, 60-5.
  30. Visvader JE, Lindeman GJ (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews. Cancer, 8, 755-68.
  31. Yao M, Yao DF, Bian YZ, et al (2011). Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. HBPD INT, 10, 289-94.

Cited by

  1. Expression of Glypican-3 is Highly Associated with Pediatric Hepatoblastoma: a Systemic Analysis vol.16, pp.3, 2015,
  2. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression vol.32, pp.8, 2017,
  3. Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation vol.7, pp.1, 2017,